While this confirmed a key role for GBM‐expressed CTRP8 as oncogenic driver in human glioblastoma, it is conceivable that H2 relaxin has a similar effect on therapeutic resistance in RXFP1+ tumors outside of the brain. This evidence concerns the gene RLN2 and glioblastoma.